stockrow
Friday 6 November 2026
Export INSM’s income statement to Excel — free account
Insmed, Inc.
INSM Healthcare Biotechnology
Insmed, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $606.4 million, up 66.7% from fiscal 2024.
- Revenue
- +268.4%
- EPS
- +73.8%
- Free cash flow
- +81.1%
- Total debt
- +0.27%
Quarter to September 2026, against a year earlier
114.36
5.60
+5.15%
Follow INSM
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
5 | 5 | 5 | 4 |
+8 more TTM periods Free account |
| (72.45%) | (87.22%) | (294.46%) | (249.28%) | ||
| (26.41%) | (38.20%) | (61.04%) | (59.53%) | ||
ROIC |
(247.55%) | (329.22%) | (1,659.95%) | 0.00% | |
Return on Tangible Assets |
(49.71%) | (67.21%) | (87.36%) | (89.39%) | |
Average Days of Receivables |
62.27 | 69.09 | 79.52 | 84.78 | |
Free Cash Flow per Share |
(2.87) | (3.72) | (4.28) | (4.86) | |
Free Cash Flow |
(627.57) | (807.67) | (921.63) | (967.57) | |
Capital Expenditures |
(31.95) | (28.75) | (25.97) | (32.56) | |
| Other line items | |||||
Cash ROIC |
(25.77%) | (32.56%) | (37.01%) | (35.43%) | |
Accounts Receivable Turnover |
9.37 | 8.42 | 7.24 | 6.29 | |
Accounts Payable Turnover |
0.48 | 0.51 | 0.51 | 0.33 | |
Inventory Turnover |
1.66 | 1.51 | 1.28 | 1.07 | |
Average Days of Payables |
884.59 | 831.80 | 863.18 | 1,354.03 | |
Days of Inventory on Hand |
252.42 | 276.12 | 325.41 | 392.11 | |
Tax Rate |
0.01 | 0.01 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
62.14% | 75.67% | 101.03% | 127.15% | |
Selling, General and Administrative Expense of Revenue |
63.19% | 78.55% | 97.72% | 115.62% | |
Share Based Compensation of Revenue |
11.01% | 13.84% | 19.43% | 25.18% | |
Interest Coverage |
(6.93) | (10.34) | (14.00) | (14.88) | |
Operating CF/Net income |
0.98 | 0.89 | 0.76 | 0.73 | |
Depreciation/Fixed assets |
0.30 | 0.26 | 0.26 | 0.25 | |
Capex/Depreciation |
(0.98) | (1.02) | (0.97) | (1.28) | |
Revenue per Share |
6.95 | 5.23 | 3.80 | 3.05 | |
Operating CF per Share |
(2.72) | (3.58) | (4.16) | (4.70) | |
Capex per Share |
(0.15) | (0.13) | (0.12) | (0.16) | |
Capex to Sales |
0.02 | 0.03 | 0.03 | 0.05 |
Columns are period end dates · fundamentals updated 2 Nov 2026